Avancées et synthèse des derniers congrès : ASCO-GU, EAU, AUA, ASCO concernant la prise en charge médicale des cancers urothéliaux

[1]  R. Huddart,et al.  BC2001: A multicenter phase III randomized trial of standard versus reduced volume radiotherapy for muscle invasive bladder cancer (ISCRTN:68324339). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Groshen,et al.  Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ- confined node-negative urothelial bladder cancer (UBC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Perkins,et al.  A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Olsson,et al.  665 SUB STAGING OF T1 BLADDER TUMOURS , 2009 .

[5]  D. Gillatt,et al.  120 PROGNOSTIC FACTORS FOR UPPER TRACT TRANSTITONAL CELL CARCINOMA AND METACHRONOUS UROTHELIAL TUMOURS: EVALUATING 888 PATIENTS FROM THE BAUS SECTION OF ONCOLOGY UROLOGICAL CANCER OBSERVATORY PROJECT , 2009 .

[6]  J. Witjes,et al.  651 IMMUNOTHERAPY OR CHEMOTHERAPY AS LOCAL THERAPY OF URINARY BLADDER CANCER – WHICH IS THE MOST EFFECTIVE? REPORT ON A META-ANALYSIS OF THE LONG-TERM OUTCOME OF RANDOMIZED STUDIES COMPARING INTRAVESICAL MITOMYCIN C VERSUS BACILLUS CALMETTE-GUERIN FOR NON-MUSCLE INVASIVE BLADDER CANCER , 2009 .

[7]  M. Habib,et al.  1015 HOLMIUM LASER ABLATION OF RECURRENT SUPERFICIAL BLADDER TUMOURS UNDER TOPICAL ANAESTHESIA USING A FLEXIBLE CYSTOSCOPE IN ANTICOAGULATED PATIENTS , 2009 .

[8]  S. Rorive,et al.  647 WHAT IS THE LONG TERM PROGNOSTIC VALUE OF PROAPOPTOTIC, ANTI-APOPTOTIC, PROLIFERATION AND INVASIVENESS MOLECULAR MARKERS IN PATIENTS TREATED WITH BCG FOR HIGH RISK NON-INVASIVE BLADDER CANCER? , 2009 .

[9]  Luke Vale,et al.  1011 PHOTODYNAMIC DIAGNOSIS OF BLADDER CANCER COMPARED WITH WHITE LIGHT CYSTOSCOPY , 2009 .

[10]  N. Fleshner,et al.  645 LONG-TERM FOLLOW-UP FOR PRIMARY T1 HIGH-GRADE BLADDER CANCER. DOES BCG REALLY PREVENT PROGRESSION? , 2009 .

[11]  E. Solsona,et al.  655 LONG-TERM FOLLOW UP OF THE EFFECTIVENESS OF STANDARD DOSE BCG (81 MG. CONNAUGHT STRAIN) COMPARING WITH A THREE FOLD REDUCE DOSE (27 MG.) IN HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER. CUETO GROUP , 2009 .

[12]  H. Grossman,et al.  1010 HEXVIX® FLUORESCENCE CYSTOSCOPY IMPROVES DETECTION AND RESECTION OF PAPILLARY BLADDER CANCER AND REDUCES EARLY RECURRENCE: A MULTICENTRE, PROSPECTIVE, RANDOMIZED STUDY , 2009 .

[13]  S. Landolfi,et al.  646 SECOND-TUR OF INITIAL HIGH GRADE T1 BLADDER CANCER AFTER-BCG AND ACCORDING TO LAMINA PROPRIA INVASION MICROSTAGING (T1 A/B) , 2009 .

[14]  T. O'brien.  1013 ODMIT C: A PROSPECTIVE RANDOMISED MULTICENTRE TRIAL OF A SINGLE POST-OPERATIVE DOSE OF INTRAVESICAL MITOMYCIN C TO PREVENT BLADDER CANCER FORMATION FOLLOWING NEPHROURETERECTOMY FOR UPPER TRACT TCC (UTTCC) , 2009 .

[15]  C. Iselin,et al.  664 PROGNOSTIC VALUE OF THE SUB-CLASSIFICATION T1 IN THE MICRO-INVASIVE BLADDER CANCER ON A MEDIUM TERM BASIS , 2009 .

[16]  H. Olsson,et al.  SUB STAGING OF T1 BLADDER TUMOURS , 2009 .